Merck Gains Clinical Oncology Program Through Aton Acquisition; Lead Agent In Phase II
This article was originally published in The Pink Sheet Daily
Executive Summary
Aton’s suberoylanilide hydroxamic acid would be Merck’s only oncologic in later-stage clinical trials. The acquisition is the second recent example of how Merck is branching into new therapeutic areas.